Market Challenges And Opportunities

The global amitriptyline market growth can be restricted by various side effects associated with the use of amitriptyline. The side effects of amitriptyline include nausea, vomiting, drowsiness, weakness or tiredness, nightmares, headaches, dry mouth, constipation, changes in sex drive, and others. Thus, side effects associated with the drug can shift the patient’s preference to alternative treatments. Such factors are expected to hamper the growth of the market.

Global Amitriptyline Market- Driver

Increase in the product approval by regulatory authorities: An increase in the number of product approval by regulatory authorities such as the U.S. FDA is expected to drive the market growth over the forecast period. For instance, in May 2021, Unichem Laboratories Ltd., an India-based pharmaceutical company, announced that it had received Abbreviated New Drug Application (ANDA) approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the U.S. Food and Drug Administration (USFDA), to market a generic version of ELAVIL (Amitriptyline Hydrochloride) in U.S.

Rising prevalence of mental disorders such as depression: The demand for amitriptyline is expected to increase, owing to the rise in the prevalence of mental disorders such as depression, anxiety, and others. Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder, a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. For instance, according to the fact sheet published by WHO (World Health Organization), on March 31, 2023, depression is a common mental disorder and an estimated 5% of adults suffer from depression, globally.

Global Amitriptyline Market: Restraint

Increase in the product recall: The major factors that can hamper the growth of the global amitriptyline market over the forecast period include the rise in the number of product recall. For instance, in February 2023, Apotex Inc., a Canada based pharmaceutical company, announced that they have recalled one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit. Key market players should focus on more stringent quality control and Good Manufacturing Practices (GMP) to obtain superior product quality.

Key market players should focus on adoption of good manufacturing practices (GMP) to reduce the contamination of their products

Global Amitriptyline Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak, in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting the production and demand for drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regard to the transportation of drugs and vaccines from one place to another.

Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending. Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively.

However, the COVID-19 pandemic had a positive impact on the global amitriptyline market due to increasing use of amitriptyline to treat post COVID-19 symptoms. For instance, according to an article published in National Library of Medicine, in July 2021, titled “Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors,” headache is one of the most frequent symptoms of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and amitriptyline was found effective to treat patient with post-COVID-19 symptoms such as headache, migraine, and others.

Moreover, COVID-19 pandemic has increased the prevalence of mental disorder, thus, it is also expected to have had positive impact on the market. For instance, according to WHO, in March 2022, the COVID-19 pandemic has had a severe impact on the mental health and wellbeing of people around the world, and also raising concerns of increased suicidal behavior and increased mental disorders.